- Home
- HQI vs CRDF Comparison
HQI vs CRDF Comparison
Compare HQI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- CRDF
- Stock Information
- Founded
- HQI 2002
- CRDF 1999
- Country
- HQI United States
- CRDF United States
- Employees
- HQI N/A
- CRDF N/A
- Industry
- HQI Professional Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HQI Consumer Discretionary
- CRDF Health Care
- Exchange
- HQI Nasdaq
- CRDF Nasdaq
- Market Cap
- HQI 140.2M
- CRDF 144.4M
- IPO Year
- HQI N/A
- CRDF N/A
- Fundamental
- Price
- HQI $9.70
- CRDF $2.15
- Analyst Decision
- HQI Buy
- CRDF Strong Buy
- Analyst Count
- HQI 1
- CRDF 5
- Target Price
- HQI $13.00
- CRDF $11.10
- AVG Volume (30 Days)
- HQI 6.7K
- CRDF 1.0M
- Earning Date
- HQI 11-06-2025
- CRDF 11-06-2025
- Dividend Yield
- HQI 2.45%
- CRDF N/A
- EPS Growth
- HQI N/A
- CRDF N/A
- EPS
- HQI 0.17
- CRDF N/A
- Revenue
- HQI $32,610,000.00
- CRDF $545,000.00
- Revenue This Year
- HQI N/A
- CRDF N/A
- Revenue Next Year
- HQI $1.38
- CRDF N/A
- P/E Ratio
- HQI $51.24
- CRDF N/A
- Revenue Growth
- HQI N/A
- CRDF N/A
- 52 Week Low
- HQI $8.94
- CRDF $1.90
- 52 Week High
- HQI $15.75
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- HQI 48.27
- CRDF 44.11
- Support Level
- HQI $9.65
- CRDF $1.97
- Resistance Level
- HQI $10.07
- CRDF $2.27
- Average True Range (ATR)
- HQI 0.35
- CRDF 0.12
- MACD
- HQI 0.00
- CRDF 0.04
- Stochastic Oscillator
- HQI 39.76
- CRDF 67.57
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.